{"slug":"tesamorelin","verification":{"valid":true,"entries":3,"head":"44e64c3ee65f1c89bf293517c0592345f045c306b572ff4f19860e1bcd569fff"},"count":3,"models":["grok-4.3"],"yield":{"passes":3,"energy_spent_rows":0,"total_cost_usd":0,"waste_cost_usd":0,"total_tokens":0,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok-4.3","passes":3,"cost_usd":0,"tokens_total":0,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T17:02:00.279Z","model":"grok-4.3","role":"writer","action":"draft","payload":{"title":"tesamorelin","register":"standard","body":"## Overview\nEvidence is being populated by Grok web search.","claims":[],"sources":[]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"24b3f450bec2390a00bad077c0d43c08fe7d2b012d89788c539a79400f565a09"},{"seq":1,"id":"k2","ts":"2026-06-29T17:02:16.853Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s1","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/41545261/","title":"Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials","quote":"Tesamorelin improves body composition, hepatic fat, lean body mass, and IGF-1 levels in HIV-associated lipodystrophy, without serious side effects","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39813152/","title":"Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity","quote":"Tesamorelin, a growth hormone-releasing hormone, reduces AO and increases IGF-1, suggesting that it might mitigate NCI in people with HIV and viral suppression.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT06554717","title":"Tesamorelin as an Adjunct to Exercise for Improving Physical Function and Muscle Health in Adults With HIV (TRIUMPH Trial)","quote":"The goal of this clinical trial is to learn whether the medication tesamorelin will improve physical function and muscle health in adults with HIV when combined with exercise.","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"24b3f450bec2390a00bad077c0d43c08fe7d2b012d89788c539a79400f565a09","hash":"2f7e2e52bf644143d11909969ffdf4d9b5e2588f675c9e1d87f10b407ea2540a"},{"seq":2,"id":"k3","ts":"2026-06-29T17:02:38.960Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38905488/","title":"Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors","quote":"The current analysis provides the first dedicated data on the efficacy and safety of tesamorelin among PWH on INSTI-based regimens. Despite the association of INSTI use with weight gain and adipose tissue dysfunction, tesamorelin had beneficial effects on body composition with no exacerbation of glycemic control.","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07481734","title":"Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)","quote":"This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease.","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 2","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"2f7e2e52bf644143d11909969ffdf4d9b5e2588f675c9e1d87f10b407ea2540a","hash":"44e64c3ee65f1c89bf293517c0592345f045c306b572ff4f19860e1bcd569fff"}]}